Peroxisome proliferator-activated receptor (
PPAR)-γ is highly expressed in human and rodent placentas. Nevertheless, its function remains obscure. The present study investigated the effects of
rosiglitazone, a
PPAR-γ agonist, on LPS-induced
fetal death. All pregnant mice except controls were intraperitoneally injected with LPS (150 μg/kg) daily from gestational day (GD)15 to GD17. As expected, maternal LPS injection caused placental
inflammation and resulted in 63.6%
fetal death in dams that completed the pregnancy. Interestingly, LPS-induced fetal mortality was reduced to 16.0% when pregnant mice were pretreated with RSG. Additional experiment showed that
rosiglitazone pretreatment inhibited LPS-induced expressions of
tumor necrosis factor (Tnf)-α,
interleukin (Il)-1β,
Il-6,
macrophage inflammatory protein (Mip)-2 and keratinocyte-derived
chemokine (Kc) in mouse placenta. Although
rosiglitazone had little effect on LPS-evoked elevation of
IL-10 in amniotic fluid, it alleviated LPS-evoked release of TNF-α and MIP-2 in amniotic fluid. Further analysis showed that pretreatment with
rosiglitazone, which activated placental
PPAR-γ signaling, simultaneously suppressed LPS-evoked
nuclear factor kappa B (NF-κB) activation and blocked nuclear translocation of NF-κB p65 and p50 subunits in trophoblast giant cells of the labyrinth layer. These results provide a mechanistic explanation for
PPAR-γ-mediated anti-inflammatory activity in the placentas. Overall, the present study provides additional evidence for roles of
PPAR-γ as an important regulator of placental
inflammation.